Ekso Bionics (NASDAQ:EKSO) Releases Earnings Results

Ekso Bionics (NASDAQ:EKSO) posted its quarterly earnings results on Monday. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02), Yahoo Finance reports. The company had revenue of $4.95 million during the quarter, compared to analyst estimates of $5.34 million. Ekso Bionics had a negative return on equity of 95.36% and a negative net margin of 79.48%. During the same period last year, the company posted ($0.31) earnings per share.

Ekso Bionics Price Performance

NASDAQ EKSO traded down $0.39 during trading on Tuesday, reaching $1.09. 575,249 shares of the company traded hands, compared to its average volume of 132,083. Ekso Bionics has a 1-year low of $0.62 and a 1-year high of $3.13. The company has a market cap of $19.81 million, a price-to-earnings ratio of -1.13 and a beta of 1.51. The stock’s 50 day moving average price is $1.16 and its two-hundred day moving average price is $1.47. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.11 and a current ratio of 2.81.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Ekso Bionics in a research report on Tuesday. Lake Street Capital began coverage on shares of Ekso Bionics in a research report on Monday, June 24th. They set a “buy” rating and a $2.50 target price on the stock. Finally, StockNews.com began coverage on Ekso Bionics in a research report on Tuesday. They issued a “hold” rating for the company.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.